This inventor holds 3 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Bayer Aktiengesellschaft, Bayer Healthcare Aktiengesellschaft. Active years: 1998-2005.
Company Filing History:
2 out of 12,266 
1 out of 77 Years Active: 1998-2005
Title: Innovations by Inventor Wolfgang Karl from Odenthal, DE
Introduction
Wolfgang Karl is an accomplished inventor based in Odenthal, Germany. He holds three patents, each contributing significantly to the field of medicinal chemistry and central nervous system treatments. His innovative work embodies the spirit of scientific advancement and dedicated research.
Latest Patents
One of Wolfgang Karl's notable patents is titled "Benzisothiazolyl-substituted aminomethyl chromanes for treating diseases of the central nervous system." This invention focuses on chromans and their preparation processes, emphasizing their potential use in developing medicaments aimed at treating disorders affecting the central nervous system.
Another significant patent by Karl involves "Methods for decomposing quinolones and naphthyridones." This innovation showcases his expertise in addressing complex chemical compounds, further indicating his commitment to improving therapeutic solutions.
Career Highlights
Throughout his career, Wolfgang Karl has been affiliated with prominent pharmaceutical corporations such as Bayer Aktiengesellschaft and Bayer Healthcare Aktiengesellschaft. His tenure at these organizations has allowed him to explore advanced medicinal chemistry, contributing to various projects that enhance health outcomes through innovative drug development.
Collaborations
Karl has collaborated with notable colleagues, including Dietrich Scherling and Dietrich Seidel. These partnerships have facilitated a dynamic exchange of ideas and techniques, fostering a collaborative environment that stimulates innovation and progress in their respective fields.
Conclusion
In conclusion, Wolfgang Karl's contributions to medicinal chemistry, as evidenced by his patents and collaborations, signify his valuable presence in the innovation landscape. His work continues to impact the research community, providing new avenues for treating critical health issues affecting the central nervous system.